318 related articles for article (PubMed ID: 25840981)
1. PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor.
Luo H; Hong H; Slater MR; Graves SA; Shi S; Yang Y; Nickles RJ; Fan F; Cai W
J Nucl Med; 2015 May; 56(5):758-63. PubMed ID: 25840981
[TBL] [Abstract][Full Text] [Related]
2. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
Luo H; England CG; Graves SA; Sun H; Liu G; Nickles RJ; Cai W
J Nucl Med; 2016 Feb; 57(2):285-90. PubMed ID: 26541778
[TBL] [Abstract][Full Text] [Related]
3.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z
Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877
[TBL] [Abstract][Full Text] [Related]
5. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
[TBL] [Abstract][Full Text] [Related]
6. PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site-Inhibited Factor VII.
Nielsen CH; Jeppesen TE; Kristensen LK; Jensen MM; El Ali HH; Madsen J; Wiinberg B; Petersen LC; Kjaer A
J Nucl Med; 2016 Jul; 57(7):1112-9. PubMed ID: 27013699
[TBL] [Abstract][Full Text] [Related]
7.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
8. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
9. Immuno-PET of tissue factor in pancreatic cancer.
Hong H; Zhang Y; Nayak TR; Engle JW; Wong HC; Liu B; Barnhart TE; Cai W
J Nucl Med; 2012 Nov; 53(11):1748-54. PubMed ID: 22988057
[TBL] [Abstract][Full Text] [Related]
10. PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment.
Shi S; Orbay H; Yang Y; Graves SA; Nayak TR; Hong H; Hernandez R; Luo H; Goel S; Theuer CP; Nickles RJ; Cai W
J Nucl Med; 2015 Jun; 56(6):927-32. PubMed ID: 25883125
[TBL] [Abstract][Full Text] [Related]
11. (64)Cu-labeled peptide for PET of breast carcinomas expressing the Thomsen-Friedenreich carbohydrate antigen.
Kumar SR; Gallazzi FA; Quinn TP; Deutscher SL
J Nucl Med; 2011 Nov; 52(11):1819-26. PubMed ID: 21984800
[TBL] [Abstract][Full Text] [Related]
12.
Pyo A; Yun M; Kim HS; Kim TY; Lee JJ; Kim JY; Lee S; Kwon SY; Bom HS; Kim HS; Kim DY; Min JJ
J Nucl Med; 2018 Feb; 59(2):340-346. PubMed ID: 28916621
[TBL] [Abstract][Full Text] [Related]
13. PET of vascular endothelial growth factor receptor expression.
Cai W; Chen K; Mohamedali KA; Cao Q; Gambhir SS; Rosenblum MG; Chen X
J Nucl Med; 2006 Dec; 47(12):2048-56. PubMed ID: 17138749
[TBL] [Abstract][Full Text] [Related]
14. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
16. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice.
Jeong JM; Hong MK; Chang YS; Lee YS; Kim YJ; Cheon GJ; Lee DS; Chung JK; Lee MC
J Nucl Med; 2008 May; 49(5):830-6. PubMed ID: 18413379
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
18. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
England CG; Jiang D; Hernandez R; Sun H; Valdovinos HF; Ehlerding EB; Engle JW; Yang Y; Huang P; Cai W
Mol Pharm; 2017 Oct; 14(10):3239-3247. PubMed ID: 28825843
[TBL] [Abstract][Full Text] [Related]
19. PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging.
Hong H; Yan Y; Shi S; Graves SA; Krasteva LK; Nickles RJ; Yang M; Cai W
Mol Pharm; 2015 Feb; 12(2):403-10. PubMed ID: 25581441
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
